Breast cancer is the most common malignancy in women, resulting in the second most frequent Abstract Background: Human breast carcinoma cell lines express high-affinity interleukin-4 receptors (IL-4R). We examined the expression and structure of these receptors on primary and cultured breast carcinoma cell lines and normal breast epithelial cells. We also tested the antitumor activity in vitro and in vivo of a fusion protein comprised of circular permuted IL-4 and truncated Pseudomonas exotoxin, termed IL-4(38-37)-PE38KDEL. Materials and Methods: Eight different primary cell cultures and cell lines of human breast carcinomas were examined for the expression of IL-4R by radiolabeled binding, reverse transcription polymerase chain reaction (RT-PCR) and Northern analyses, and subunit structure by crosslinking studies. The antitumor activity of IL-4 toxin was tested in vitro by cytotoxicity assays and in vivo in a xenograft model in immunodeficient animals. Results:
I-IL-4 specifically bound to primary cell cultures and cell lines with a Kd ranging between 0.2 and 1 nM. Breast tumor cells were found to express IL-4Rͱ and IL-13RͰЈ chains, but not IL-2RͲ c chain. These cells were highly sensitive to the cytotoxic effect of IL-4(38-37)-PE38KDEL. The IC 50 (concentration inhibiting protein synthesis by 50%) ranged between approximately 0.005-1.5 nM. A normal breast epithelial cell culture was not sensitive to the cytotoxic activity of IL-4(38-37)-PE38KDEL. MDA-MB231 human breast carcinoma cell line formed a rapidly growing tumor in nude mice. Intratumor and intraperitoneal administration of IL-4(38-37)-PE38KDEL caused a dose dependent regression of established tumors. A control toxin, anti-Tac(Fv)-PE38KDEL, targeted to the IL-2 receptor Ͱ chain did not cause regression of these tumors. Conclusions: These results suggest that IL-4(38-37)-PE38KDEL may be a useful agent for targeting of IL-4 receptor positive human breast carcinomas and further studies should be performed to explore fully its potential.
cancer cells may help generate targeted antibreast cancer agents. Recently, various fusion proteins have been produced that are designed to target human breast cancers. For example, Heregulin-Pseudomonas exotoxin, which the ligand Heregulin binds to ErbB-2, ErbB-3 and ErbB-4 receptors, is connected to a truncated form of Pseudomonas exotoxin (PE). This cytotoxin is highly cytotoxic in vitro and in vivo to breast cancer cells that overexpress ErbB-4 or ErbB-2 plus ErbB-3 receptors (2) . A recombinant epidermal growth factor (EGF) Genistein conjugate, in which EGF was conjugated to soybean-derived protein tyrosine kinase inhibitor, was targeted to an EGF-receptor and was found to be cytotoxic to the EGF-receptor positive breast cancer cells (3) . A recombinant, humanized moncloclonal antiHer2 antibody (Herceptin) was able to significantly inhibit growth of breast cancer in an animal model and in the clinic (4) . This antibody synergized with paclitaxel when mediating antitumor activity against breast tumor xenograft models. Herceptin was recently licensed by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. These studies demonstrate that these classes of biotherapeutics can provide an additional mode of breast cancer therapy, although their clinical benefits have yet to be completely explored. It is possible that additional breast tumor-associated receptors or antigens will be identified that may provide new targets for breast cancer therapy.
We and others have identified that human breast cancer cell lines express elevated levels of the receptor for an immune regulatory cytokine, interleukin-4 (IL-4) (5-7). Although the functional significance of this receptor on breast cancer cell lines is not clear, IL-4 can inhibit proliferation of these cells in vitro and induce apoptosis (5-7). It is not known whether these receptors are overexpressed in situ in breast carcinomas. We reported that IL-4 receptors were expressed in situ in renal cell carcinoma and AIDS-associated Kaposi's sarcoma (8, 9) . Thus, it is likely that breast carcinoma may also express IL-4 receptors in vivo, because breast cancer cell lines express receptors in high numbers. We also found that a variety of solid cancer cells overexpress high-affinity IL-4 receptors (IL-4R) (10) (11) (12) . These receptors are functional because IL-4 is able to cause signal transduction, inhibit growth, upregulate major histocompatibility (MHC) antigens and intercellular adhesion molecule-1 (ICAM-1) on cancer cells (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . IL-4R also are expressed, although in low numbers, in normal immune cells such as T cells; B cells; monocytes; other blood cells, such as eosinophils, basophils, and fibroblasts; and endothelial cells (10, 11) . The significance of the overexpression of IL-4R on epithelial cancer cells and the similarities and differences between IL-4R in cancer cells and immune cells is not completely clear.
IL-4 receptors have been shown to be comprised of a 140 kDa protein originally termed IL-4RͰ (20) . Because of similarities in extracellular domains (WSXWS motif and four cysteine residues at a fixed location) and long intracellular domains between the IL-4RͰ and ͱ chains of receptors for IL-3, IL-5, and granulocytemacrophage colony stimulating factor (GM-CSF), we have recently proposed to rename this chain IL-4Rͱ (18, 21) . This recommendation also was based on its similarity with the IL-2Rͱ chain, which like IL-4R p140, binds IL-2, but does not transmit a signal on its own (22) . The second subunit of the IL-4R system was shown to be a component of the IL-2 receptor system, the Ͳ chain (22, 23) . Because IL-2RͲ chain also was shown to be a component of IL-7, IL-9, and IL-15 receptor systems (24) (25) (26) , it was named Ͳ c . Thus, the IL-4Rͱ chain and Ͳ c form type I IL-4 receptors. Recently, we demonstrated by reconstitution experiments that a 60-70 kDa protein form of interleukin-13 receptor (IL-13R) can substitute for Ͳ c when mediating IL-4 signaling and, thus, this chain forms a third subunit of the IL-4R system (IL-13RͰЈ also termed as IL-13RͰ 1 ) (18, 21, 27, 28) . Consequently, IL-4Rͱ and IL-13RͰЈ chains form type II IL-4 receptors. Whether all three chains form an IL-4R complex in cancer cells is not known. It is also not known whether breast cancer cells express Type I or Type II IL-4 receptors. The differences in subunit structure between IL-4R in cancer cells and normal immune cells are also not completely known. We demonstrated that the Ͳ c chain expressed in immune cells was not expressed on human solid cancer cell lines (11, 18, 29) . Instead, these cells expressed the IL-13RͰЈ (or Ͱ 1 ) chain along with the IL-4Rͱ chain (29, 30) . Further studies on the structure and function of IL-4R on cancer cells are ongoing. Regardless of differences in IL-4R between normal and cancer cells, we have been able to exploit the overexpression of IL-4R on cancer cells by targeting them with a cytotoxic chimeric protein comprised of IL-4 and PE (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) .
In the present study, we employed a circularly permuted form of IL-4-toxin [IL-4(38-37)-PE38KDEL], which contained amino acids 38-129 of IL-4 fused via a peptide linker to amino acids 1-37. These are, in turn, fused to amino acids 353-364 and 381-608 of PE, with KDEL at positions 609-612 (37) . This IL4-toxin has potent cytotoxic activity against eight different breast cancer cell lines and primary cell cultures. We also investigated the expression and structure of IL-4 receptors in breast cancer cell lines, primary cell cultures and a breast epithelial cell line. We tested the antitumor activity of IL-4(38-37)-PE38KDEL against human breast cancer in vivo in a xenograft model. Our data support further studies on the use of IL-4(38-37)-PE38KDEL for possible treatment of metastatic breast cancer.
Materials and Methods

Recombinant Cytokines and Toxins
Recombinant circularly permuted IL-4-toxin, IL-4(38-37)-PE38KDEL, was produced and purified to Ͼ95% homogeneity as described previously (32, 33, 37, 38) . Recombinant IL-4 was produced as described (43) .
Cell Lines
The primary cultures of human breast carcinoma R-BT, S-BT, and W-BT were established and kindly provided by Dr. Magda Sgagias, Surgery Branch, National Cancer Institute (Bethesda, MD) (44) . The breast carcinoma cell lines (MCF-7, BT-20, SK-BR3, ZR-75-1, and MDA-MB231) were obtained from the American Type Culture Collection (ATCC), Rockville, MD. Dr. Sgagias also provided one primary epithelial cell culture from normal breast tissue (A-NL). The primary tumor and normal breast cell cultures were cultured in medium comprised of Ͱ-minimum essential medium, HAM's F-12, EGF, triiodothionine, N-2-hydroxy ethylpiperazine-N-2-ethanesulfonic acid (HEPES) ascorbic acid, estradiol, insulin, hydrocortisone, ethanolamine, transferrin, bovine pituitary extract, sodium selenite, glutamine, gentamicin, penicillin, and streptomicin. The breast carcinoma cell lines were cultured in complete media, comprised of RPMI 1640, 10% heat inactivated fetal calf serum (FCS) and gentamycin. These adherent cell lines were routinely passaged every 4-5 days.
Animals
Four-week-old female athymic nude mice (~20 g) were obtained from Frederick Cancer Center Animal Facilities (Frederick, MD). Animals were housed in filter-top cages in a laminar flow hood.
Protein Synthesis Inhibition Assay
The cytotoxic activity of IL-4-toxins was tested as previously described by determining inhibition of protein synthesis (31 Following a 2 hr incubation, cell-bound radio-ligand was separated from unbound by centrifugation through a phthalate oil gradient and radioactivity was determined with a gamma counter (Wallac). The number of receptors and binding affinities were determined as previously described (12) . : leupeptin (10 Ȑg/ml), trypsin inhibitor (100 Ȑg/ml), pepstatin (10 Ȑg/ml), benzamidine HCl (10 mM), phenanthroline (1 mM) iodoacetamide (20 mM), e-aminocaproic acid (50 mM) and phenyl methyl sulfonic fluoride (PMSF) (1 mM). The resulting lysate was cleared by boiling in sample buffer containing 2-mercaptoethanol and analyzed by electrophoresis through a SDS-PAGE (8%) gel, as previously described (15) . The gel was dried and exposed to X-ray film for 7 days to obtain an autoradiograph.
Affinity Cross Linking of 125 I-IL-4 to Its
For immunoprecipitation, the [ 125 I]-IL-4/IL-4R cross-linked complex was immunoprecipitated from the lysate prepared from MCF-7 cells overnight at 4ЊC by incubating with protein A sepharose beads that had been preincubated with anti-Ͳ c or anti-IL-4Rͱ chain antibody. The resulting conjugate was washed twice with solubilizing buffer, diluted with reducing buffer, boiled for 5 min and analyzed by SDS-PAGE, as described above. The gel was dried and autoradiographed.
Northern Analysis for IL-4R Subunits
Total RNA was isolated using TRIZOL reagent (GIBCO BRL, Gaithersburg, MD). Equal amounts of total RNA were electrophoresed through a 0.8% agarose/formaldehyde denaturing gel, transferred to a nylon membrane (S&S Nytran; Schleicher and Schuell, Keene, NH) by capillary action and immobilized by ultraviolet crosslinking (Stratagene, Inc., La Jolla, CA). The membrane was then prehybridyzed for 4 hr at 42ЊC and hybridized with 32 P-labeled cDNA probes of IL-4Rͱ, IL-13RͰЈ, and Ͳ c at 42ЊC overnight. The membranes were subsequently exposed to X-AR film (Eastman Kodak Co. Rochester, NY) to obtain an autoradiogram.
RT-PCR Analysis
RT-PCR analysis was performed as previously described (40) . Total RNA was isolated from cell lines using Tri-Reagent (Molecular Research Center, Inc. Cincinnati, OH) following the manufacturer's instructions. The concentration and purity of total RNA was determined by spectrophotometric analysis. One Ȑg of total RNA was used in the RT-PCR assay. RT-PCR conditions were as follows: 95ЊC for 5 min, 1 cycle; 95ЊC for 1 min; 72ЊC for 1 min; 72ЊC for 1 min, 30-35 cycles; and 72ЊC for 10 min for the final primer extension sequence. RT-PCR primers for IL-4Rͱ: 5Ј primer, 5'-ATGGGGTGGCTTTGCTCTGGG-3Ј and 3Ј primer, 5Ј-ACCTTCCCGAGGAAGTTCGGG-3Ј; for Ͳ c , 5Ј primer, 5Ј-CCAGAGGTTCAGTGTTTT-GTGTT-3' and 3Ј primer, 5Ј-CAGGTTTCAGG-ATTTAGGGTGTA-3Ј; for IL-13RͰЈ: 5Ј primer, 5Ј GGAGGATACATCTTGTTTCATGG-3Ј and 3Ј primer, 5Ј-GAGCTTCTTACCTATACTCATTTC-TTGG-3Ј. The IL-4Rͱ RT-PCR cDNA product was 316 bp; 256 bp; for Ͳ c and 148 bp for IL-13RͰЈ. A 100 bp DNA ladder (GIBCO BRL Life Technologies Inc., Gaithersburg, MD) was used as a base pair reference marker.
Antitumor Activity of IL-4-Toxin in Nude Mice Implanted with Human Breast Tumor
Human breast tumor nodules were established in nude mice by subcutaneous injection of 3-4 ϫ 10 6 MDA-MB231 cells in 100 Ȑl of phosphate-buffered saline (PBS) containing 0.2% human serum albumin (HSA) into the abdomen on day 0. Palpable tumors developed within 3-5 days. Tumor size was calculated by muliplying two perpendicular diameters.
Two routes for administration of IL-4 (38-37)-PE38KDEL were employed: intraperitoneal (i.p.) and intratumoral (i.t.). The mice were i.p.-injected with 100 Ȑl excipient or 50, 100 or 150 Ȑg/kg twice daily for 5 consecutive days. Another group of mice was slowly i.t.-injected (20 Ȑl) with excipient or an IL-4(38-37)-PE38KDEL dose of 250 Ȑg/kg/dose on days 8, 10 and 12. Each injection was placed into a different area of the tumor. An additional group of mice was i.t.-injected with chimeric toxin at a dose of 750 Ȑg/kg/dose on days 8, 10 and 12, followed by reinjection with 500 Ȑg/kg/dose on days 22, 24 and 26. A third group of animals were i.t.-injected with 750 Ȑg/kg/dose on days 22, 24 and 26, followed by reinjection with 500 Ȑg/kg/dose on days 36, 38, and 40.
Statististics
The significance of differences in mean tumor sizes among treatment groups was analyzed by unpaired Student's t-test. All p-values are presented as two-sided analysis.
Results
Cytotoxicity of IL-4-toxins Against Breast Carcinoma Cell Lines and Primary Cell Cultures
IL-4-toxins, including IL-4(38-37)-PE38KDEL, have been shown to have cytotoxic activity against cell lines that express IL-4 receptors (IL-4R) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . However, it is not known whether primary cell cultures of human breast carcinoma express IL-4R and if they do, whether these cells and breast cancer cell lines are susceptible to the cytotoxic activity of IL-4-toxins. We tested four primary cell cultures of breast carcinoma generated from four patients undergoing surgical resection for their cancer, as previously described (44) . Three of four primary cell cultures were sensitive to the cytotoxic activity of circular permuted IL-4-toxin and one of these three was extremely sensitive to IL-4(38-37)-PE38KDEL ( Fig. 1A and Table  1 ). The IC 50 (the concentration of toxin causing inhibition of protein synthesis in target cells by 50%) ranged between 0.2 to 240 ng/ml (4 pM to 4.8 nM). The cytotoxic activity of IL-4(38-37)-PE38KDEL was specific, as an excess of recombinant IL-4 neutralized the cytotoxic activity of IL-4-toxin to primary breast carcinoma cell culture R-BT (Fig. 1A) .
Like primary cell cultures, breast carcinoma cell lines were also very sensitive to the cytotoxic activity of IL-4-toxin. Protein synthesis was inhibited in a concentration-dependent manner against four of five breast cancer cell lines examined. The IC 50s for IL-4(38-37)-PE38KDEL ranged between 0.4 ng/ml to 75 ng/ml (8 pM to 1.5 nM) (Fig. 1B and Table 1 ).
Inhibition of 125 I-IL-4 Binding by IL-4-toxins on MCF-7 Breast Carcinoma Cell Line
To determine the binding affinity of IL-4(38-37)-PE38KDEL to breast cancer cells, we performed displacement assays where [ (Fig. 2) (39,40) . The EC 50 (protein concentration required for 50% inhibition of 125 I-IL-4 binding) for IL-4(38-37)-PE38KDEL was ~0.5 nM and for IL-4 it was ~0.4 nM. These data suggested that IL-4(38-37)-PE38KDEL bound to IL-4R with similar affinity to IL-4 and circular permutation or fusion of PE did not modify its binding affinity to breast cancer cells. 
IL-4R Expression on Breast Carcinoma Cell Lines and Primary Cultures
We previously reported that human breast carcinoma cell lines express high-affinity IL-4R (5) . In binding studies, we found that a primary cell culture of breast carcinoma (R-BT) also bound to radiolabeled IL-4 in a concentration-dependent manner. Displacement analysis revealed that these receptors were of high affinity (~1 nM). MDA-MB231 and MCF-7 breast cancer cell lines also expressed high-affinity IL-4R (~0.2 nM) (Fig. 3) . The number of binding sites/cell was calculated by single point binding assay and found to vary in different cell types (Table 1) .
Crosslinking of 125 I-IL-4 to Breast Carcinoma Cells
The structure of IL-4R on two different breast carcinoma cell lines was examined next. This was performed by crosslinking radiolabeled IL-4 to surface IL-4R, followed by SDS-PAGE under reducing conditions (Fig. 4A) . [
125 I]-IL-4 crosslinked to two prominent proteins at approximately 155 kDa and 85 kDa on both breast cancer cell lines (lanes 1 and 4) . In addi- To confirm the identity of [ 125 I]-IL-4-IL-4R cross-linked complexes, immunoprecipitation with anti-IL-4R antibody was performed before electrophoresis on SDS-gel. As shown in Fig. 4A (lanes 3 and 6) , all three prominent bands were immunoprecipitated, indicating that all these proteins formed an IL-4R complex on breast carcinoma cells.
RT-PCR and Northern Analysis of IL-4R Subunits on Breast Carcinoma Cells
We next examined the expression of IL-4Rͱ, IL-13RͰЈ and Ͳ c chains, all of which can form IL-4R complexes in different cell types. As shown in Figure 5 , RT-PCR products of 316 bp for IL-4Rͱ and 148 bp for IL-13RͰЈ chain were expressed in all of the studied breast carcinoma cell lines and primary cell cultures. In contrast, most breast cancer cell lines did not express the 255 bp Ͳ c product, but it was detected in R-BT primary breast tumor cell culture (Fig. 5, lane 4) .
To confirm whether the Ͳ c chain was expressed in breast cancer cell lines and primary cell cultures, we performed Northern analysis to examine mRNA for IL-4Rͱ, IL-13RͰЈ and Ͳ c chains. As shown in Fig. 6 , IL-4Rͱ and IL-13RͰЈ mRNA was abundantly expressed in all breast cancer cell lines and primary breast cancer cell cultures, however, mRNA for the Ͳ c chain was not expressed in any cell lines. These data supported our crosslinking studies and futher demonstrated that IL-4Rͱ and IL-13RͰЈ chains formed an IL-4R complex on breast carcinoma cells and Ͳ c did not form a complex, as seen in immune cells. These data indicated that breast tumor cells expressed type II IL-4 receptors. ), the mice were injected i.t. with varying doses of IL-4 toxin, as specified in "Materials and Methods." Anti-tac-immunotoxin, which binds to the IL-2 receptor Ͱ chain, served as a negative control since breast cancer cells may not express IL-2 receptors. The treatment began 8 days after tumor implantation and these animals received two additional injections on days 10 and 12. IL-4-toxin treatment caused a dose-dependent regression of breast tumors (Fig. 7A) , as the antitumor effect was more pronounced at the higher dose (750 Ȑg/kg). Although the tumors began to grow again 10 days after the last dose of toxin, the growth rate of tumors in treatment groups was significantly slower, compared with the control group. For example, on day 45 after intratumor administration of IL-4-toxin, the lowest dose (250 Ȑg/kg) caused a significant inhi- Animals that received the highest dose (750 Ȑg/kg) of IL-4-toxin on days 8, 10 and 12 after tumor implantation received additional intratumor doses (500 Ȑg/kg) of IL-4-toxin on days 22, 24 and 26. These mice again showed further decrease in tumor size, however, these tumors continued to grow until the end of the experiment. The tumor sizes in this group were significantly lower, compared with the control, anti-Tac-immunotoxin group or lowerdose treated groups (p Ͻ 0.0005 vs. control, p Ͻ 0.0001 vs. anti-Tac-immunotoxin and p Ͻ 0.05 vs. 250 Ȑg/kg). The control mice were sacrificed and the experiment was terminated on day 59, because of heavy tumor burden in accordance with the guidelines of NIH Animal Research Advisory Committee.
Antitumor activity of IL-4-toxin
An additional five animals were also i.t. injected with IL-4(38-37)-PE38KDEL when tumors had almost doubled in size and reached 36 mm 2 . These animals received 750 Ȑg/kg of IL-4-toxin on days 22, 24 and 26, followed with 500 Ȑg/kg of IL-4-toxin on days 36, 38 and 40. The growth of these large tumors also was slowed, compared with control tumors (data not shown). These animals were sacrificed on day 52 due to large tumors.
In another experiment, cohorts of five nude animals bearing subcutaneous human breast cancer xenografts were given intraperitoneal injections with escalating doses of IL-4(38-37)-PE38KDEL. These injections were given 2 times a day for 5 days. As shown in Fig.  7B , IL-4(38-37)-PE38KDEL caused regression of established breast cancer nodules in a dose-dependent manner. At the highest dose (150 Ȑg/kg/dose), one of the five animals showed complete regression of the established tumor. The size of the tumor in the remaining four animals continued to be significantly smaller, compared with any other groups, including controls (p Ͻ 0.05 control vs. 100 Ȑg/kg dose; p Ͻ 0.006 control vs. 150 Ȑg/kg dose). The tumors continued to grow in control animals, eventually reaching about 65 mm 2 . All animals were sacrificed due to large tumor burdens.
Sensitivity of Breast Tumor Cultures after in vivo Passage and IL-4-toxin Therapy
To determine whether breast tumor cells acquired resistance after in vivo passage or after IL-4-toxin therapy, tumors were excised from control and IL-4-toxin-treated animals. Single cell suspensions were prepared by enzyme digestion and the resulting cells were passaged at least once before cytotoxicity of IL-4(38-37)-PE38KDEL was determined. The sensitivity to IL-4(38-37)-PE38KDEL, as well as the IC 50 , was similar on cells derived from control animals and IL-4-toxin treated animals. The IC 50 was also similar to that observed in cells not injected into animals (not shown).
Discussion
We have demonstrated that human breast cancer cells are highly sensitive to the cytotoxic activity of a IL-4 receptor targeted chimeric toxin comprised of IL-4 and a mutated form of PE. Recombinant IL-4(38-37)-PE38KDEL was also active in vivo and caused regression of established breast tumors in a xenograft model. Intraperitoneal and intratumoral administration of IL-4(38-37)-PE38KDEL caused significant antitumor activity in a breast tumor model without any significant systemic toxicity.
Breast cancer cell lines and primary cell cultures express high-affinity receptors for IL-4 on their cell surface. The receptor numbers vary with the cell lines. There does not appear to be a correlation between sensitivity to IL4-toxin and number of IL-4 receptors. R-BT cells are very sensitive to the cytotoxic activity of the IL-4-toxin, even though they express the lowest number of IL-4 receptors. A normal breast epithelial cell culture was not sensitive to the cytotoxic activity of IL-4-toxins, indicating that normal breast epithelial cells may not express or express very low levels of IL-4R. IL-4(38-37)-PE38KDEL appears non-cytotoxic to resting normal human lymphoid cells, indicating that this agent could be useful for breast cancer therapy without affecting normal cells.
The structure of IL-4R on breast cancer cell lines was assessed by affinity crosslinking studies. Radiolabeled IL-4 crosslinked to two prominent proteins migrating at 140 and 65 kDa and none of these bands were observed when crosslinking was performed in the presence of an excess of unlabeled IL-4. The 140 and 65 kDa molecular mass of these crosslinked proteins corresponded to IL-4Rͱ and IL-13RͰЈ chain, respectively, as per our previous nomenclature (18) . IL-13RͰЈ has been shown to be a novel and essential component of the IL-4 receptor system in cells that do not express IL-2RͲ c (27) . Breast cancer cells did not express IL-2RͲ c chain, as antibody to IL-2RͲ c did not immunoprecipitate IL-4 receptor components in crosslinking studies (not shown). The lack of Ͳ c chain expression was confirmed by RT-PCR and Northern analysis, while mRNA for IL-4Rͱ and IL-13RͰЈ was abundantly expressed. These results indicate that breast carcinoma cells express type II IL-4 receptors (18, 29) . Our data confirm previous results demonstrating that IL-4(38-37)-PE38KDEL has significant antitumor activity in vitro and in vivo (37) (38) (39) (40) (41) (42) . We have reported that IL-4(38-37)-PE38KDEL can cause complete regression of established human epidermoid carcinoma and glioma tumors in nude mouse models (38, 42) . Based on those studies, it was assumed that breast cancer cell lines that expressed IL-4R would also be sensitive to the cytotoxic activity of IL-4(38-37)-PE38KDEL. However, expression of IL-4 receptors on primary breast tumor cultures and sensitivity of these cultures and tumor cell lines to IL4-toxins had not been demonstrated. Our current studies confirm previous assumptions and demonstrate that IL-4 receptor positive breast cancer cells are generally sensitive to IL-4(38-37)-PE38KDEL. Since five of nine cell lines and primary cell cultures were highly sensitive, it is believed that IL-4(38-37)-PE38KDEL may have a major role in the management of patients with breast cancer.
In vitro sensitivity to IL-4(38-37)-PE38KDEL has been shown to generally correlate with in vivo antitumor activity against epidermoid and brain tumor models (38, 42) . However, it was not known whether in vitro sensitivity of breast cancer cells to IL-4(38-37)-PE38KDEL would correlate with in vivo antitumor activity. Although we observed significant antitumor activity against breast tumors when injected i.t., complete regression of the tumor was not observed in this model, as seen in human glioma models, even though equal doses of IL-4(38-37)-PE38KDEL were administered via the same route. In addition, systemic (intraperitoneal) administration of IL-4(38-37)-PE38KDEL required more frequent injections to cause significant regression of tumors. The reason for different sensitivity to IL-4-toxin is not clear. MDA-MB231 cells used for in vivo studies were as sensitive as U251 glioma cells to IL-4-toxin (IC 50 for both cell lines ranged between 2-4 ng/ml). It is possible that trafficking of IL-4(38-37)-PE38KDEL to breast cancer nodules is more restricted, compared with U251 glioma nodules. This is likely because single cell suspensions from treated nodules maintained their sensitivity to IL-4(38-37)-PE38KDEL. It is known that tumor nodules often develop physiological barriers restricting the ability of many macromolecules to home to tumor cells (45) . Enhancement of the permeability of tumor vasculature may increase sensitivity of these tumors to targeted toxins.
In contrast to i.p. and i.t. routes, administration of IL-4(38-37)-PE38KDEL by the i.v. route did not demonstrate significant antitumor activity in the breast tumor model (data not shown). This observation is in contrast to that observed in the brain tumor model, in which IL-4(38-37)-PE38KDEL demonstrated significant antitumor activity when injected by the i.v. route (42) . Due to short serum half-life (t 1/2 ϭ 10 min) (38) of IL-4(38-37)-PE38KDEL, i.v. administered drug is not available in sufficient quantity to mediate antitumor activity in the breast tumor model. Any manipulation that increases serum half-life may enhance antitumor activity of IL-4-toxin. One way to achieve this would be to administer IL-4(38-37)-PE38KDEL by continuous infusion using a 5-day cycle. Alternatively, co-administration of agents that can increase vascular permeability for a short period of time may improve drug availability to tumors. In this regard, IL-2 a T cell-derived cytokine, has been shown to increase capillary permeability in various models and in patients undergoing IL-2 therapy for cancer (46) . Concurrent administration of IL-2 may not only increase drug trafficking, it may also improve antitumor activity against breast cancer through host immune activation. These hypotheses must be tested in preclinical models.
Other immunotoxins targeted to breast cancer have been tested in preclinical models and in the clinic. A B3 antibody that recognizes carbohydrate antigen (Le y ) on many human solid cancers when attached to various mutated forms of PE (B3-PE, B3-Lys-PE40 or B3-Lys-PE38) has shown significant antitumor activity against breast cancer and other tumor models (47, 48) . Similarly, another antibody (BR96) targeted to the Le y antigen when chemically conjugated to doxorubicin or conjugated or fused to PE has shown significant antitumor activity against breast cancer models (49,50). In a phase I clinical trial, B3-LysPE38 also showed some antitumor activity against breast cancer (48) . IL-4(38-37)-PE38KDEL appears to be similar in activity to B3-LysPE38, BR96-doxorubicin (BR96-dox) or BR96 sFV-PE40 in breast cancer model, as shown in the current study. However, it is noteworthy that the size of IL-4(38-37)-PE38KDEL is considerably smaller than B3-PE, B3-Lys-PE38, BR96-dox or BR96 sFV-PE40. Furthermore, in a clinical trial, B3-LysPE38 caused vascular leak syndrome, presumably through the activation and lysis of endothelium and other normal tissues. Since smaller molecules may have better tumor penetration and IL-4(38-37)-PE38KDEL has less reactivity to normal tissues, it is likely that IL-4(38-37)-PE38KDEL would be better tolerated with improved antitumor activity. Additional comparative studies are needed to address this issue. Furthermore, since all these agents target different antigens or receptors on breast cancer cells, it is possible that a combination therapy with two of these agents may have synergistic antitumor activities against breast cancer.
In conclusion, circular permuted IL-4-toxin, IL-4(38-37)-PE38KDEL, may be a useful therapeutic agent for the treatment of human breast cancer because a majority of human breast carcinoma cell cultures and lines expressed high levels of IL-4R and were sensitive to its cytotoxic activity. Further in vivo studies should be performed to explore the role of IL-4(38-37)-PE38KDEL in breast cancer models.
